Informations générales (source: ClinicalTrials.gov)
Evaluation of the Animal Intervention Used as Therapy. Impact of Animal-assisted Therapy on the Well-being in Patients With Alzheimer's Disease (ELIAUT)
Interventional
N/A
Hospices Civils de Lyon (Voir sur ClinicalTrials)
mars 2016
mai 2019
29 juin 2024
The animal-assisted therapy (AAT) is now considered a non-drug care and is often used in
geriatrics. Many studies have shown a link between the presence of the animal and the
psycho-behavioral symptoms decrease in dementia (PBSD) such as depression, anxiety or
irritability that affects their quality of life and improved cognitive abilities.
However, many methodological flaws in these researches exist.
The aim of the study is to evaluate the effectiveness of AAT on the well-being of
patients with Alzheimer disease (AD) at the stage of Major Neuro Cognitive Disorder (NCD)
at short and medium term (before care, during care (at the beginning and end of each
session), 1 week after, 2 weeks and 1 month after the last session) compared to a group
receiving the same stimulation without the dog's response.
Patients will be seen in groups of 4 to 6 people at 8 workshops. 2 groups will be formed:
AAT group versus control group. The only difference between these two groups is the
intervention of the dog at each workshop in the AAT group.
Each workshop will consist of three identical times. It will begin with a 15 minute
introductory activity, the first goal will be to establish a relationship with patients
(patients-patients and patients-caregivers) and a 40 minute cognitive stimulation,
identical in the 2 groups, will be proposed and finally 5 minutes will be devoted to the
closing of the session This study should highlight a positive effect of animal assisted
therapy on the well-being, PBSD, depression, anxiety and cognitive abilities and a
long-term retention of these positive effects.
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Hôpital des Charpennes - 69100 - Villeurbanne - France | Contact (sur clinicalTrials) | ||||
Critères
Tous
Inclusion Criteria:
Enrolled patients should have been informed and should not oppose the research, by
themselves or through a trusted person, failing this, by the family, or, by a close
person maintain stable ties; Subject aged over 65 years fulfilling the criteria of
Alzheimer's disease the major NCD stage with or without vascular disorders; Ambulatory
patient in Charpennes Day Hospital ; Being affiliated to health insurance.
Enrolled patients should have been informed and should not oppose the research, by
themselves or through a trusted person, failing this, by the family, or, by a close
person maintain stable ties; Subject aged over 65 years fulfilling the criteria of
Alzheimer's disease the major NCD stage with or without vascular disorders; Ambulatory
patient in Charpennes Day Hospital ; Being affiliated to health insurance.
Patients with signs and symptoms suggestive of dementia related to other diseases than AD
or mixed forms ; Patients with progressive and unstable pathologies which could interfere
with the variables under consideration ; Deafness or blindness which could compromise the
evaluation of the patient or his involvement during the sessions ; Patient being under
guardianship ; Patient refusing the work with a animal ; Patient allergic to dogs ;
Patient ending his care prior to the 13 weeks required for the study. Exclusion criteria
will be sought during the questioning of the patient and his relatives as well as the
review of his medical file (organic and neuroradiological explorations).